; (C) the deployment of diagnostic and treatment capacity in areas with the highest tuberculosis burdens, as well as for highly at-risk and impoverished populations, including patient support; (D) program monitoring and evaluation based on critical tuberculosis indicators, including infection control, the numbers of patients accessing tuberculosis treatment, along with patient support, and preventative therapy for those at risk, including all close contacts, as well as treatment completion for all forms of tuberculosis; (E) training health care workers on the use of new diagnostic tools and therapies as they become available; (F) coordination with domestic agencies on an aggressive research agenda to develop vaccines as well as new tools to diagnose, treat, and prevent tuberculosis globally; (G) linkages with the private sector on improved diagnosis and treatment of tuberculosis, training for healthcare professionals on use of the most effective diagnostic and therapeutic tools, and research in the areas of vaccine development as well as the development of therapeutics and diagnostic tools; (H) efforts to address barriers to patients seeking care including stigma and costs related to diagnosis and treatment; (I) efforts to address human rights-related barriers to tuberculosis services, including— (i) training health workers; (ii) sensitizing policy makers; (iii) legal literacy and patient empowerment campaigns; (iv) strengthening legal services; and (v) monitoring laws and policies